Aurion Biotechnologies

Also Clin1/Clin2 corneal endothelial disease

Aurion Biotechnologies is a clinical-stage biotechnology company focused on developing innovative, accessible, and effective advanced therapies for ocular diseases. Their mission is to restore vision to millions of patients through regenerative medicine. Aurion Biotech's lead product, AURN001, is an allogeneic cell therapy candidate for the treatment of corneal edema secondary to corneal endothelial disease. This condition can lead to significant vision loss and blindness. AURN001 has received both Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation from the FDA. Aurion Biotech has completed enrollment and dosing of its Phase 1/2 clinical trial for AURN001 in the United States and Canada. Additionally, the company has received regulatory approval for AURN001 in Japan, making it the first allogeneic, clinically validated cell therapy for corneal endothelial disease.